Bemarituzumab (Anti-FGFR2 / CD332) | FGFR | Read Reviews & Product Use Citations

Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Click to purchase the isotype control of Bemarituzumab (Anti-FGFR2 / CD332)

Selleck's Bemarituzumab (Anti-FGFR2 / CD332) has been cited by 0 Publication

1 Customer Review

Purity & Quality Control

Batch: A249701 Purity: 99% Protein concentration: 3.55mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective FGFR Inhibitors

Biological Activity

Description	Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Product Details

CAS No.	1952272-74-0
Molecular Weight	145.24 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field